A Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose, Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TAK-906 in Japanese Healthy Male Subjects
Phase of Trial: Phase I
Latest Information Update: 22 Mar 2019
Price : $35 *
At a glance
- Drugs TAK 906 (Primary)
- Indications Gastroparesis
- Focus Adverse reactions
- Sponsors Takeda
- 19 Oct 2017 Status changed from recruiting to completed.
- 03 Aug 2017 Status changed from not yet recruiting to recruiting.
- 03 Aug 2017 New trial record